Dallah Healthcare Co's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 110.74.
Dallah Healthcare Co's Days Inventory for the
three
months ended in Mar. 2026 was 49.24.
Dallah Healthcare Co's Days Payable for the
three
months ended in Mar. 2026 was 56.39.
Therefore, Dallah Healthcare Co's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 103.59.
Dallah Healthcare Co (SAU:4004) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Dallah Healthcare Co Cash Conversion Cycle Related Terms
Dallah Healthcare Co Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Dallah Healthcare Co's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SAU:4004 vs HCA, THC, DVA: Cash Conversion Cycle Comparison
For the Medical Care Facilities subindustry, Dallah Healthcare Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dallah Healthcare Co Cash Conversion Cycle vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Dallah Healthcare Co's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Dallah Healthcare Co's Cash Conversion Cycle falls into.
Dallah Healthcare Co Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Dallah Healthcare Co's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dallah Healthcare Co (SAU:4004) has a Cash Conversion Cycle of 103.59 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Dallah Healthcare Co and its competitors.
Is Dallah Healthcare Co's Cash Conversion Cycle too high?
Dallah Healthcare Co's current Cash Conversion Cycle is 103.59. The Healthcare Providers & Services industry median Cash Conversion Cycle is 18.01. Dallah Healthcare Co's value of 103.59 is 475.3% above this industry median. Overall, Dallah Healthcare Co has a GF Score™ of 92/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Dallah Healthcare Co's Cash Conversion Cycle compare to HCA and THC?
Dallah Healthcare Co's Cash Conversion Cycle of 103.59 can be compared against companies in the Healthcare Providers & Services industry. The industry median Cash Conversion Cycle is 18.01. Dallah Healthcare Co's value of 103.59 is 475.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Healthcare Providers & Services company?
The median Cash Conversion Cycle among Healthcare Providers & Services companies is 18.01, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dallah Healthcare Co's current Cash Conversion Cycle of 103.59 is 475.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Dallah Healthcare Co and its competitors. For the Healthcare Providers & Services industry, the median Cash Conversion Cycle is 18.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dallah Healthcare Co's current Cash Conversion Cycle is 103.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dallah Healthcare Co stock overvalued right now?
Based on GuruFocus' analysis, Dallah Healthcare Co (SAU:4004) is currently considered Possible Value Trap. The stock's GF Value™ is ﷼206.94, compared to a current price of ﷼108.00 — trading 47.8% below its estimated fair value. The current Cash Conversion Cycle is 103.59 and 475.3% above the Healthcare Providers & Services industry median of 18.01. Dallah Healthcare Co's overall GF Score™ is 92/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Dallah Healthcare Co (SAU:4004), the current Cash Conversion Cycle is 103.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dallah Healthcare Co (SAU:4004) Overvalued in 2026?
Based on GuruFocus' analysis, Dallah Healthcare Co stock appears to be undervalued.
The current stock price of ﷼108.00 is trading 47.8% below its estimated GF Value™ of ﷼206.94.
GuruFocus considers Dallah Healthcare Co to be Possible Value Trap.
Key valuation signals for SAU:4004:
Cash Conversion Cycle: 103.59
GF Value™: ﷼206.94 vs. price of ﷼108.00 (47.8% below fair value)
Industry Position: 475.3% above the Healthcare Providers & Services median
No single metric tells the full story. See the SAU:4004 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dallah Healthcare Co provides and operates healthcare programs and utilities in the Kingdom of Saudi Arabia. The objectives of the company include operating, managing, and maintaining the healthcare entities, wholesale medicines, and retail of medical and surgical equipment, prosthetics, and devices for the disabled, hospital equipment, and manufacturing medicines, pharmaceuticals, herbals, health, cosmetics, detergents, disinfectants, and packaging in the Kingdom of Saudi Arabia. The reportable segments of the company are Medical Facilities and Pharmacies, and Distribution of Pharmaceutical Products. The company generates the majority of its revenue from the Medical Facilities and Pharmacies segment.
92GF Score
Get the complete analysis for SAU:4004
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:4004 has been successfully added to your 
